|
|
Press Releases
2008 Press Releases
 |
Thursday, May 8, 2008
Pilot Study to Assess Safety and Efficacy of Medidur™ FA in AMD Patients Treated With Lucentis®
Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company announced today that enrollment has begun for a pilot study to assess the safety and efficacy of Medidur FA in conjunction with Lucentis® (ranibizumab injection, Genentech) in patients with exudative age-related macular degeneration (wet AMD).
HTML |  PDF |
|
Tuesday, March 24, 2008
DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur™ FA for the Treatment of DME
After completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study can continue under the current protocol, without change. The trial is studying the use of Medidur FA for the treatment of diabetic macular edema (DME).
HTML | PDF |
|
Tuesday, March 18, 2008
Alimera Sciences Closes $30 Million In Series C Financing, Increasing Stake In Medidur™ FA
Alimera Sciences today announced that it has closed a Series C financing round of $30 million with all five of the company’s existing venture capital firms exercising the right to participate at their full pro rata share.
HTML | PDF |
|
Monday, March 17, 2008
Alimera Sciences, pSivida Limited Amend Medidur™ FA Collaboration Agreement
Alimera Sciences and pSivida Ltd today announced that they have amended their license and collaboration agreement relating to Medidur™ FA, the companies’ Phase III investigative treatment for diabetic macular edema (DME), and other Medidur products.
HTML | PDF |
|
Tuesday, February 26, 2008
Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants
Alimera Sciences has entered into a second exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment for ophthalmic diseases.
HTML | PDF |
2007 Press Releases |
|
Wednesday, October 17, 2007
DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur™ FA for the Treatment of DME
After completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that the pivotal Phase 3 clinical trial FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change. The trial is studying the use of Medidur FA for the treatment of diabetic macular edema (DME).
HTML | PDF |
|
Monday, October 08, 2007
Enrollment Complete In Pivotal Phase 3 Trial of Medidur™ FA for Diabetic Macular Edema
Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company, and pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI), announced today that enrollment is complete for the FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study of Medidur™ FA for the treatment of Diabetic Macular Edema. FAME is a double masked, randomized, multi-center study that is following over 900 patients in the U.S., Canada, Europe and India for 36 months with safety and efficacy assessed at two years. Alimera Sciences and pSivida are jointly developing Medidur FA under a collaborative research and development agreement.
HTML | PDF |
|
Monday, September 10, 2007
Alimera Sciences Signs Agreement with Emory University for Potential Treatments Using Novel Class of Antioxidants
ATLANTA — Alimera Sciences will enter into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment for ophthalmic diseases. The agreement, announced today, gives Alimera the exclusive option to license a unique class of compounds, which are NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidase inhibitors, as a potential treatment for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy.
HTML | PDF |
|
Wednesday, August 22, 2007
Enrollment Begins on Human PK Study for Medidur FA
ATLANTA — Alimera Sciences, a privately held ophthalmic pharmaceutical company, and pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that enrollment has begun for the first human pharmacokinetic (PK) study of fluocinolone acetonide (FA) in Medidur™, the companies’ investigational product for the treatment of diabetic macular edema (DME).
Medidur is a tiny insert, injected intra-vitreally during an in-office procedure, which is being studied as a way to deliver a very low dose of fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years as a treatment for DME. Medidur FA is currently in a Phase III global clinical trial, the FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study that will follow approximately 900 patients in the U.S., Canada, Europe and India for three years with safety and efficacy assessed at two years. Enrollment for this study has currently exceeded 750 patients.
HTML | PDF |
|
Wednesday, August 1, 2007
Bausch & Lomb Acquires Soothe® Emollient (Lubricant) Eye Drops from Alimera Sciences; Expands Product Line
ROCHESTER, N.Y. and ATLANTA — Bausch & Lomb (NYSE: BOL) today announced its acquisition of Soothe emollient (lubricant) eye drops from Alimera Sciences, a privately-held ophthalmic pharmaceutical company. Financial terms were not disclosed.
Bausch & Lomb will expand upon the Soothe brand’s success, establishing a broader line of professionally-recommended, over-the-counter products to relieve dry eye symptoms. The company will initially focus on two technologies, each designed to target a different layer of the tear film.
HTML | PDF |
|
Monday, April 23, 2007
Alimera Sciences’ Medidur™ Trial Exceeds 500 Patient Mark In Phase 3 Trial Enrollment
Alimera Sciences, a privately held ophthalmic pharmaceutical company, and global drug delivery company pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that enrollment for their Phase 3 global clinical trial, the FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study has exceeded 50 percent. FAME is a double masked, randomized, multi-center study that will follow approximately 900 patients in the U.S., Canada, Europe and India for 36 months. The trial is studying the safety and efficacy of the novel treatment currently referred to as Medidur for diabetic macular edema (DME).
HTML | PDF |
2006 Press Releases |
|
Wednesday, December 20, 2006
Alimera Sciences and Bausch & Lomb Announce Transaction For Alaway™ OTC Eye Care Product
ATLANTA, GA AND ROCHESTER, NY – Alimera Sciences, a privately-held company headquartered in Atlanta, GA and Bausch & Lomb (NYSE:BOL) today announced that Bausch & Lomb has purchased Alimera’s OTC allergy franchise, including Alaway (ketotifen fumarate ophthalmic solution 0.025%), which was recently approved by the U.S. Food and Drug Administration.
HTML | PDF |
|
Tuesday, December 5, 2006
Alimera Sciences Receives FDA Approval to Market Alaway™ OTC for Up To 12 Hours of Eye Itch Relief
Alimera Sciences Inc., an ophthalmic pharmaceutical company founded just three years ago, today announced that the U. S. Food and Drug Administration (FDA) has approved its ophthalmic solution Rx–to-OTC-switch new drug application (NDA) for Alaway™ (ketotifen fumarate ophthalmic solution 0.025%). Alaway™, a multiple action eye anti-allergic, is Alimera’s first NDA submission and the first to win approval. Indicated for the temporary relief of itchy eyes, Alaway™ will be marketed over-the-counter with the prescription strength active ingredient found in a prescription allergy eye drop.
HTML | PDF |
|
Monday, November 27, 2006
Alimera Sciences Completes Second Tranche of Series B Financing, Receives $15.9 Million
Alimera Sciences Inc., an ophthalmic pharmaceutical company, announced today that it has completed the second tranche of its Series B financing, receiving $15.9 million in additional venture capital. This represents the culmination of the Company’s Series B financing of $31.8 million secured in November 2005, at which time Alimera received an initial $15.9 million in proceeds.
HTML | PDF |
|
Monday, July 17, 2006
Alimera Sciences Announces Agreement with CYNACON / OCuSOFT®, to Co-Promote OCuSOFT® Lid Scrub Eyelid Cleanser
Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, and CYNACON / OCuSOFT, a broad based supplier of ophthalmic pharmaceuticals and supplies, today announced an agreement for Alimera Sciences sales representatives to begin detailing and sampling the OCuSOFT® Lid Scrub family of eyelid cleansers to existing ophthalmic and optometric customers.
HTML | PDF |
|
Monday, March 20, 2006
Data Safety Monitoring Board Recommends Continuation
Of Medidur™ Phase III Clinical Trial
Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, and pSivida Limited, a global bio-nanotech company, announced today that following a planned interim review, an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of its Phase 3 clinical trial of Medidur™.
HTML | PDF |
|
Wednesday, January 25, 2006
Alimera Sciences Names Proven Atlanta Executive Eiswirth New CFO
Alimera Sciences Inc., an ophthalmic pharmaceutical company, today announced the appointment of Richard S. Eiswirth as the company’s chief financial officer. Active in Atlanta’s business circles for more than 15 years, Eiswirth’s portfolio includes entrepreneurial and consulting experience with numerous key business transactions including mergers, acquisitions and initial public offerings. HTML | PDF |
2005 Press Releases |
|
Wednesday, November 30, 2005
Alimera Sciences Secures $31.8 Million in Series B Financing
Alimera Sciences Inc., an ophthalmic pharmaceutical company, announced today that it has completed Series B financing, securing $31.8 million in venture capital. Premier venture firm Venrock Associates led the new round, and all four original Series A firms continued their investment. HTML | PDF |
|
Monday, October 3, 2005
Alimera Sciences, in Collaboration with Control Delivery Systems, Initiates Phase III Trial for Retinal Condition
Alimera Sciences Inc., a dynamic ophthalmic pharmaceutical company, in collaboration with Control Delivery Systems Inc. (CDS), a leader in innovative drug delivery systems for the eye, recently initiated a Phase III clinical trial to study diabetic macular edema (DME) patients treated using Medidur™ with fluocinolone acetonide, the companies’ pharmacologic treatment for DME. HTML | PDF |
|
Monday, May 9, 2005
Alimera Sciences Launches Online Consumer Ordering
Alimera Sciences Inc., a dynamic ophthalmic pharmaceutical company, today announced that its Soothe® Emollient (Lubricant) Eye Drops are now available for purchase over the Internet. To order the over-the-counter eye drops, consumers and professionals can visit www.sootheeyedrops.com or link from Alimera Sciences' home page HTML | PDF |
|
Monday, March 21, 2005
Alimera Sciences Initiates JCAHPO'S "Partner For Learning" Program
Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, today announced that it will support the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) in 2005 as its first "Partner for Learning." HTML | PDF |
|
Monday, March 7, 2005
Alimera Sciences Names Phil Tracy Chairman of the Board
Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, today named Phil Tracy, J.D., chairman of the company's board of directors. HTML | PDF |
|
Wednesday, February 16, 2005
Alimera Sciences and Control Delivery Systems announce collaboration agreement on a new pharmacologic treatment for diabetic macula edema - Implant may provide three-year, sustained drug delivery
Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, and Control Delivery Systems Inc. (CDS), a leader in innovative drug delivery systems for the eye, today announced a worldwide agreement to co-develop and market a new pharmacologic treatment indicated for diabetic macular edema (DME), a major cause of vision loss in people suffering from diabetic retinopathy. HTML | PDF |
|
Wednesday, January 26, 2005
Alimera Sciences Funding Earns "Deal of the Year"
Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, announced that the company was awarded the Georgia Biomedical Partnership (GBP) inaugural Deal of the Year award for its 2004 Series A financing of $26.75 million. HTML | PDF |
2004 Press Releases
|
Wednesday, October 20, 2004
Alimera Partners with VISTAKON Pharmaceuticals to Distribute Soothe
Alimera Sciences Inc., a dynamic ophthalmic pharmaceutical company, today announced that it has entered into a co-promotion agreement with VISTAKON Pharmaceuticals, LLC to market Soothe™, Alimera Sciences’ recently launched emollient (lubricant) dry-eye drops. HTML | PDF |
|
Friday, August 13, 2004
Alimera Launches Market's First Dry-Eye Emollient (Lubricant) Drop
Alimera Sciences' first product, Soothe™, available September 15
Alimera Sciences Inc., a dynamic ophthalmic pharmaceutical company, today unveiled Soothe™ Emollient (lubricant) Eye Drops, the market's first multi-dose, emollient-based artificial tear product. Soothe offers over-the-counter relief to the 12 million Americans suffering from dry eye, a condition resulting from the body's inability to produce enough tears to keep the eye surface lubricated. HTML | PDF |
|
Friday, July 21, 2004
Alimera Sciences Announces Its Board of Directors
Alimera Sciences Inc., a new kind of ophthalmic pharmaceutical company, today announced its board of directors, which includes funding partner representatives and
one of ophthalmology's most distinguished professionals. HTML | PDF |
|
Friday, July 9, 2004
Atlanta-Based Alimera Sciences Debuts with $26.75 Million in Series A
Financing
Alimera Sciences Inc., a recently formed specialty pharmaceutical
company focused on the ophthalmic industry, announced today that
it has received $26.75 million in Series A financing. The funds will
be used for acquisition and continued development of the
company's ophthalmic pharmaceutical pipeline and for the
commercialization of the company's over-the-counter
ophthalmic products. HTML | PDF |
|
|
